Symptoms and Association with Health Outcomes in Relapsing-Remitting Multiple Sclerosis: Results of a US Patient Survey
Table 1
Characteristics of the sample.
Demographics
(%)
Age, mean (SD)
49.3 (11.5)
Female
314 (70.2%)
Race
White
345 (77.2%)
Black
64 (14.3%)
Hispanic
28 (6.3%)
Asian
5 (1.1%)
Other
5 (1.1%)
Employed
182 (40.7%)
College graduate
164 (36.7%)
Have health insurance
407 (91.1%)
General health characteristics
(%)
BMI
Underweight
9 (2.0%)
Normal weight
132 (29.5%)
Overweight
138 (30.9%)
Obese
162 (36.2%)
Decline to answer
6 (1.3%)
Exercise in previous month
247 (55.3%)
Smoke cigarettes
103 (23%)
Drink alcohol
260 (58.2%)
Charlson comorbidity index, mean (SD)
0.40 (0.98)
MS characteristics
(%)
Years diagnosed with MS, mean (SD)
12.3 (9.0)
Treatment status
Currently treated
360 (80.5%)
Disease modifying treatment only
299 (66.9%)
Disease modifying treatment w/dalfampridine/other
25 (5.6%)
Only dalfampridine/other
36 (8.1%)
Formerly treated
48 (10.7%)
Never treated
39 (8.7%)
Self-reported severity of MS
Mild
194 (43.4%)
Moderate
231 (51.7%)
Severe
22 (4.9%)
Note: disease-modifying medications include interferon 1a or 1b, glatiramer acetate, fingolimod, mitoxantrone, or natalizumab. Dalfampridine is a treatment to improve walking difficulties in MS and is not disease modifying.
